Description
Indication
Halobetasol Propionate 0.05% is a super-high potent corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the Hypothalamic-Pituitary-Adrenal (HPA) axis.
Pharmacology
Like other topical corticosteroids, Halobetasol Propionate has anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of the anti-inflammatory activity of the topical corticosteroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Dose and Administration
Apply a thin layer of HalobetTM Cream or Ointment to the affected skin once or twice daily, as directed by the physician, and rub in gently and completely. Halobetasol Propionate 0.05% is a super-high potency corticosteroid; therefore, treatment should be limited to two weeks, and amounts greater than 50 g/week should not be used. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Halobetasol Propionate should not be used with occlusive dressings. Use in Halobet TM Halobetasol Propionate children under 12 years of age is not recommended.
Contraindications
Halobetasol Propionate is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Side Effects
The taking after antagonistic impacts have been detailed rarely with topical corticosteroids. These responses incorporate burning, tingling, dryness, folliculitis skin break out, hypopigmentation, perioral dermatitis, unfavorably susceptible contact dermatitis, skin decay, auxiliary diseases, striae and miliaria.
Pregnancy and Lactation
Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Therefore caution should be exercised when topical corticosteroids are administered to a nursing woman.
Precaution and Warnings
Systemic absorption of topical corticosteroids may cause reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, manifestations of cushing’s syndrome, hyperglycemia, and glucosuria. Patients receiving large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Safety and effectiveness of Halobetasol Propionate cream & ointment in paediatric patients have not been established. Paediatric patients are at greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids.
Therapeutic Class
Other Topical corticosteroids
Storage Conditions
Store below 300. Do not freeze. Keep all medicines out of reach of children
Reviews
There are no reviews yet.